Approval · Notice of Compliance 22376 · 2019
VYVANSE: Notice of Compliance 22376
Issued July 8, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22376
- Date
- July 8, 2019
- Company
- Shire Pharma Canada UlcToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a chewable dosage form
Products in this notice
Medicinal ingredients
- LISDEXAMFETAMINE DIMESYLATE 10 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 20 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 30 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 40 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 50 MG per TAB
- LISDEXAMFETAMINE DIMESYLATE 60 MG per TAB